menu
    • menu

    Company profile for Hansa Biopharma

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and ...
    Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. Imlifidase is currently under review for a potential marketing authorization by European Medicines Agency (EMA).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Hansa BiopharmaSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Hansa Biopharma AB P.O. Box 785 SE-220 07 Lund
    Telephone
    Telephone
    +46 46 16 56 70
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.hansabiopharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hansa Bio Seeks FDA Approval For Imlifidase In Kidney Transplant
    Hansa Bio Seeks FDA Approval For Imlifidase In Kidney Transplant

    20 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hansa-biopharma-submits-bla-to-fda-for-imlifidase-in-desensitization-for-kidney-transplantation-302647231.html

    PR NEWSWIRE
    20 Dec 2025
    Share Share
    Hansa Bio Announces Changes to Bolster Eur., Int'l Organisation
    Hansa Bio Announces Changes to Bolster Eur., Int'l Organisation

    17 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-17/hansa-biopharma-announce-changes-to-strengthen-european-and-international-organisation

    PHARMIWEB
    17 Dec 2025
    Share Share
    Hansa Updates Pivotal Phase 3 Anti-GBM Disease Trial
    Hansa Updates Pivotal Phase 3 Anti-GBM Disease Trial

    17 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-17/hansa-provides-update-on-pivotal-phase-3-trial-in-anti-glomerular-basement-membrane-anti-gbm-disease

    PHARMIWEB
    17 Dec 2025
    Share Share
    Hansa Bio Reveals 2025 Q3 Financials Result
    Hansa Bio Reveals 2025 Q3 Financials Result

    30 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-30/hansa-biopharma-reports-third-quarter-and-interim-year-to-date-2025-financial-results

    PHARMIWEB
    30 Oct 2025
    Share Share
    Hansa Eyes FDA Nod After Kidney Transplant Drug Succeeds in Trial
    Hansa Eyes FDA Nod After Kidney Transplant Drug Succeeds in Trial

    27 Sep 2025

    // PRESS RELEASE

    https://www.hansabiopharma.com/media/press-releases/2025/imlifidase-successfully-meets-primary-endpoint-in-pivotal-us-phase-3-confides-trial-in-kidney-transplantation/

    PRESS RELEASE
    27 Sep 2025
    Share Share
    Hansa Biopharma Announces New Leadership
    Hansa Biopharma Announces New Leadership

    29 Jul 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/hansa-biopharma-makes-leadership-appointments/

    CONTRACTPHARMA
    29 Jul 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search